Accredited Wealth Management LLC Invests $334,000 in Eli Lilly and Company (NYSE:LLY)

Accredited Wealth Management LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 433 shares of the company’s stock, valued at approximately $334,000.

A number of other hedge funds have also added to or reduced their stakes in LLY. Principal Financial Group Inc. raised its holdings in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after buying an additional 60,306 shares in the last quarter. Versant Capital Management Inc grew its position in Eli Lilly and Company by 19.2% in the fourth quarter. Versant Capital Management Inc now owns 1,167 shares of the company’s stock valued at $901,000 after acquiring an additional 188 shares during the last quarter. Modus Advisors LLC raised its stake in Eli Lilly and Company by 67.0% during the fourth quarter. Modus Advisors LLC now owns 800 shares of the company’s stock worth $618,000 after acquiring an additional 321 shares in the last quarter. Everence Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 3.2% in the fourth quarter. Everence Capital Management Inc. now owns 22,340 shares of the company’s stock worth $17,246,000 after acquiring an additional 690 shares during the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Eli Lilly and Company by 13.7% in the 4th quarter. Nordea Investment Management AB now owns 1,154,350 shares of the company’s stock valued at $887,014,000 after purchasing an additional 138,835 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $825.10 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm’s fifty day simple moving average is $825.36 and its two-hundred day simple moving average is $816.37. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock has a market capitalization of $782.34 billion, a P/E ratio of 70.46, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.58 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research note on Friday, January 17th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research note on Thursday, January 16th. Truist Financial boosted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday. Finally, Guggenheim restated a “buy” rating on shares of Eli Lilly and Company in a report on Thursday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,002.80.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.